Eyelash growth in subjects treated with bimatoprost: A multicenter, randomized, double-masked, vehicle-controlled, parallel-group study

Journal of the American Academy of Dermatology

Volumn 66, Issue 5, 2012, Pages 801-806

  Smith, Stacy ^a   Fagien, Steven ^b   Whitcup, Scott M ^c   Ledon, Fred ^c   Somogyi, Christine ^c   Weng, Emily ^c   Beddingfield III, Frederick C ^c,d  

^a Therapeutics Clinical Research   (United States)

^b Allergan Inc ^*

^c ALLERGAN INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bimatoprost; digital image analysis; global eyelash assessment scale; hypotrichosis; prostamide

Indexed keywords

BIMATOPROST;

ADULT; AGED; ARTICLE; CONJUNCTIVAL DEPOSIT; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTACT DERMATITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; ECZEMA; EYE EXAMINATION; EYE INFLAMMATION; EYE IRRITATION; EYELASH; EYELID; EYELID ERYTHEMA; FEMALE; GROWTH DISORDER; HAIR DISEASE; HUMAN; HYPERPIGMENTATION; IMAGE ANALYSIS; INCIDENCE; INTRAOCULAR PRESSURE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; AGED; AMIDES; CALIFORNIA; CLOPROSTENOL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; EYELASHES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859842337     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.06.005     Document Type: Article

References (20)

1. Khong JJ, Casson RJ, Huilgol SC, Selva D. Madarosis. Surv Ophthalmol 2006;51:550-60. (Pubitemid 44667704)
2. Moses RA. The eyelids. In: Moses RA, editor. Adler's physiology of the eye: clinical application. 5th ed St Louis (MO): CV Mosby Co; 1970. pp. 1-16.
3. DeMello M. Facial hair. In: DeMello M, editor. Encyclopedia of body adornment. Westport (CT): Greenwood Publishing Group; 2007. p. 109.
4. Shaikh MY, Bodla AA. Hypertrichosis of the eyelashes from prostaglandin analog use: a blessing or a bother to the patient? [letter]. J Ocul Pharmacol Ther 2006;22:76-7. (Pubitemid 43364084)
5. Woodward DF, Liang Y, Krauss AH-P. Prostamides (prostaglandin- ethanolamides) and their pharmacology. Br J Pharmacol 2008;153:410-9. (Pubitemid 351199006)
6. Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K, et al, for the Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002;120:1286-93. (Pubitemid 36105433)
7. Whitcup SM, Cantor LB, VanDenburgh AM, Chen K, for the Bimatoprost Study Group II. A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. Br J Ophthalmol 2003;87:57-62. (Pubitemid 36071780)
8. Williams RD, Cohen JS, Gross RL, Liu C-C, Safyan E, Batoosingh AL, for the Bimatoprost Study Group. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol 2008;92:1387-92.
9. Yoelin S, Wu J, Somogyi C, Beddingfield FCI. Inter-rater and intra-rater reliability of the global eyelash assessment scale for assessment of overall eyelash prominence. Poster presented at: Skin Disease Education Foundation's 33rd Annual Hawaii Dermatology Seminar; February 7-13, 2009; Maui, HI.
10. Yoelin S, Walt JG, Earl M. Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth. Dermatol Surg 2010;36:638-49.
11. Latisse [package insert]. Irvine, CA: Allergan Inc; 2009.
12. Dmitrienko A, Molenbergh G, Chuang-Stein C, Offen W. Gatekeeping strategies. In: Analysis of clinical trials using SAS: a practical guide. Cary (NC): SAS Publishing; 2005.
13. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74. (Pubitemid 8054849)
14. Brandt JD, VanDenburgh AM, Chen K, Whitcup SM, for the Bimatoprost Study Group 1. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology 2001;108:1023-31.
15. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
16. Tauchi M, Fuchs TA, Kellenberger AJ, Woodward DF, Paus R, Lutjen-Drecoll E. Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost. Br J Dermatol 2010;162:1186-97.
17. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol 2002;47(Suppl):S185-202. (Pubitemid 35232233)
18. Mansberger SL, Cioffi GA. Eyelash formation secondary to latanoprost treatment in a patient with alopecia. Arch Ophthalmol 2000;118:718-9. (Pubitemid 30327353)
19. Study of bimatoprost solution in increasing eyelash prominence in African Americans with eyelash hypotrichosis. Available from: http://clinicaltrials. gov/ct2/show/NCT00958035. Accessed September 30, 2009.
20. Safety and efficacy study of bimatoprost to treat hypotrichosis of the eyelashes after application to the eyelid margin. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00907426. Accessed July 26, 2010.